Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

RADNOR, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in Baltimore, Maryland on December 7 and 8, 2019. 
Details for the poster presentations at the AES Annual Meeting:“Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus” R.E. Ramsay, et al.
Abstract # 1.136 
Saturday, December 7
12:00 pm to 6:00 pm
“Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects” A.M. Hussain, et al.
Abstract # 2.213 
Saturday, December 7
12:00 pm to 6:00 pm
In addition to the Main Exhibit Hall session, Abstract 1.136 was accepted for presentation at the Investigator’s Workshop Poster Session, which highlights the most outstanding abstracts on topics related to basic science and clinical research.  Details for this presentation:What: Investigator’s Workshop Poster Session
Where: Baltimore Convention Center, Room 339 – 342, Level 300
When: Sunday December 8, 2019, 12pm-1:30pm
KOL Breakfast and Live Webcast:  Update on Ganaxolone for the Treatment of Refractory Status Epilepticus (RSE)Marinus will host a KOL breakfast meeting at AES which will feature presentations by Michael A. Rogawski, MD, PhD (University of California, Davis), key opinion leader in the field of neurosteroids, as well as Joe Hulihan, MD (Chief Medical Officer of Marinus). Members of the Company’s  management team will also present further information on its recently completed Phase II trial of ganaxolone in RSE. This event is intended for institutional investors and sell-side analysts. Please RSVP in advance if you plan to attend, as space is limited.Where: Royal Sonesta Harbor Court, 550 Light Street Baltimore, MD
When: Monday, December 9, 7am to 8.30am ET
For those who are unable to attend in person, a live webcast with slides and replay of the event will be accessible hereAbout Marinus PharmaceuticalsForward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical study testing schedule and milestones, the ability to complete enrollment in our clinical studies, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, the timing of the clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, the attainment of clinical study results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.      
Lisa M. Caperelli
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.